Balt's $400M Irvine Bet to Fight Stroke and Create 700 Jobs

IRVINE, CA – May 19, 2026 – French neurovascular device specialist Balt is making a formidable statement about its U.S. ambitions, doubling down on its presence in Irvine with a second facility and a multi-year, $400 million investment strategy aimed at accelerating the development of life-saving stroke treatments. The move is set to create 700 high-skilled jobs by 2030, cementing the city's status as a global epicenter for medical technology.

The company commemorated the opening of its new manufacturing and research facility on May 12, a key milestone in a plan that will see its local workforce swell to approximately 1,200 employees. This expansion is not just about adding square footage; it's a strategic maneuver to capture a larger share of the highly competitive, multi-billion-dollar neurovascular device market.

Irvine's Rise as a Global Med-Tech Powerhouse

Balt's decision to deepen its roots in Irvine is a powerful endorsement of the city's carefully cultivated ecosystem for life sciences. The expansion is part of a previously announced strategy that earmarks over $400 million for U.S. manufacturing, infrastructure, R&D, and clinical trials between 2026 and 2030. A significant portion of that capital is flowing directly into Irvine, where Balt's campus is projected to grow to 85,000 square feet.

"Balt's growth in Irvine is a testament to our City's dynamic ecosystem," said Mayor Larry Agran in a statement. "This expansion validates Irvine's status as a global leader in healthcare innovation and medical technology."

This validation is built on a foundation of tangible assets. The broader Orange County region is often dubbed the "Medical Device Capital of the world," with over 2,000 life science companies employing more than 65,000 people. This dense concentration of talent and expertise creates a fertile ground for innovation, a fact not lost on Balt's leadership.

The proximity to elite academic institutions like the University of California, Irvine (UCI), which consistently ranks among the top for awarding biological and biomedical science degrees, provides a steady pipeline of skilled professionals. This synergy between industry and academia is crucial for a company focused on cutting-edge R&D.

"Balt's investment reflects Irvine's strength as a global center for life sciences innovation, advanced manufacturing, and high-skilled job creation," noted Karin Koch, Director of Economic Development at the City of Irvine. "The City is proud to support companies like Balt that are advancing groundbreaking medical technologies while creating meaningful economic opportunity for our community and region."

Accelerating Innovation in the Fight Against Stroke

At the heart of this expansion is a mission to combat one of the world's most devastating medical conditions. Balt specializes in creating minimally invasive devices—such as stents, catheters, and coils—used by neurointerventionalists to treat both ischemic strokes (caused by blockages) and hemorrhagic strokes (caused by bleeding).

The global market for these devices was valued at nearly $5 billion in 2025 and is projected to almost double by 2035, driven by an aging global population and a rising incidence of neurological diseases. With North America representing the largest market, a robust U.S. manufacturing and R&D presence is critical for any company with global aspirations.

Balt's expanded Irvine campus, which includes a doubling of its cleanroom space to 17,000 square feet, is designed to accelerate its product pipeline. The company plans to launch 18 new products by 2028 and is currently conducting clinical trials for its Silk Vista flow diverter, a device for treating brain aneurysms. The co-location of manufacturing, engineering, and R&D teams is intended to shorten the cycle from idea to implementation, getting life-changing devices to patients faster.

"Balt's proximity to research, development, and manufacturing teams accelerates the transfer of ideas and the development of life-changing medical devices, saving lives around the world," Mayor Agran added, highlighting the direct human impact of the investment.

A Strategic Play in a Competitive Global Arena

While the expansion brings significant local benefits, it is fundamentally a strategic play on the global stage. Founded in France in 1977, Balt established its U.S. presence in Irvine in 2016 and has since grown rapidly from a small foothold to a major operational hub.

"Over the past decade, Irvine has played a central role in Balt's growth in the United States," said Pascal Girin, CEO of Balt. "The opening of our second Irvine facility reflects our strong commitment to the U.S. market and our continued investment in Irvine as we expand our manufacturing and innovation capabilities."

This commitment is necessary to compete in a market dominated by industry giants. Companies like Medtronic, Stryker, and Penumbra hold significant market share, with the top five players controlling nearly 60% of the global neurovascular market in 2025. These competitors are also heavily invested in R&D and have extensive global footprints.

Balt's strategy appears to be one of focused innovation and regional strength. By building a powerful U.S. base in a supportive ecosystem like Irvine, the company can enhance its agility and responsiveness to the needs of American physicians and patients. This move positions Balt to challenge its larger rivals not just on scale, but on the speed and quality of its technological advancements.

"As we continue expanding our manufacturing and innovation capabilities, we are proud to deepen our commitment to a city that offers exceptional talent, a strong business environment, and a thriving ecosystem for medical technology innovation," stated Fred Gunderman, President of Balt USA.

As construction dust settles and new employees begin their work, Balt's expanded campus stands as more than just new buildings. It represents a confluence of corporate strategy, civic ambition, and medical necessity—a multi-million-dollar investment that promises not only economic returns for Irvine but also new hope for stroke patients around the world.